Abstract
Although apathy is a diagnostic term used with increasing frequency in both neurology and psychiatry, confusion still exists as to its proper definition and assessment, and whether apathy should be considered a symptom of major psychiatric diseases or an independent syndrome in its own right. Moreover, critical questions regarding the phenomenology and clinical correlates of apathy and the syndromic validity of this construct still exist. Despite these nosological concerns, there is strong evidence that apathy is a common finding in Alzheimer’s disease (AD). However, the treatment of apathy is still elusive. Current data are obtained from randomised controlled trials that did not investigate apathy per se, but rather a number of other behavioural and psychological variables. In this context, acetylcholinesterase inhibitors and psychosocial interventions are the only available modalities for treating apathy in AD with some efficacy.
Similar content being viewed by others
References
Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci 1991; 3(3): 243–54
Starkstein SE. Apathy and withdrawal. Int Psychogeriatr 2000; 12Suppl. 1: 135–8
van Reekum R, Stuss DT, Ostrander L. Apathy: why care? J Neuropsychiatry Clin Neurosci 2005; 17(1): 7–19
Marin RS, Wilkosz PA. Disorders of diminished motivation. J Head Trauma Rehabil 2005; 20(4): 377–88
Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cerebral Cortex 2006; 16(7): 916–28
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Washington, DC: American Psychiatric Association, 1994
World Health Organization (WHO). The ICD-10 classification of mental and behavioural disorders. Geneva: WHO, 1993
Marin RS. Differential diagnosis and classification of apathy. Am J Psychiatry 1990; 147(1): 22–30
Starkstein SE, Fedoroff JP, Price TR, et al. Apathy following cerebrovascular lesions. Stroke 1993; 24(11): 1625–30
Starkstein SE, Mayberg HS, Preziosi TJ, et al. Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 1992; 4(2): 134–9
Starkstein SE, Migliorelli R, Manes F, et al. The prevalence and clinical correlates of apathy and irritability in Alzheimer’s disease. Eur J Neurol 1995; 2: 540–6
Starkstein SE, Merello M. Psychiatric and cognitive disorders in Parkinson’s disease. Cambridge: Cambridge University Press, 2002
Starkstein SE, Petracca G, Chemerinski E, et al. Syndromic validity of apathy in Alzheimer’s disease. Am J Psychiatry 2001; 158(6): 872–7
Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression. J Neuropsychiatry Clin Neurosci 1998; 10(3): 314–9
Starkstein SE, Garau ML, Cao A. Prevalence and clinical correlates of disinhibition in dementia. Cogn Behav Neurol 2004; 17: 139–47
Buettner L, Fitzsimmons S. Mixed behaviors in dementia: the need for a paradigm shift. J Gerontol Nurs 2006; 32(7): 15–22
Marin RS, Butters MA, Mulsant BH, et al. Apathy and executive function in depressed elderly. J Geriatr Psychiatry Neurol 2003; 16(2): 112–6
Marin RS, Firinciogullari S, Biedrzycki RC. Group differences in the relationship between apathy and depression. J Nerv Ment Dis 1994; 182(4): 235–9
Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997; 48Suppl. 6: S10–6
Strauss ME, Sperry SD. An informant-based assessment of apathy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 2002; 15(3): 176–83
Robert PH, Clairet S, Benoit M, et al. The Apathy Inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment. Int J Geriatr Psychiatry 2002; 17(12): 1099–105
Starkstein SE, Ingram L, Garau LM, et al. On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry 2005; 76: 1070–4
Spitzer RL, Williams JB, Gibbon M, et al. The Structured Clinical Interview for DSM-III-R (SCID): I. History, rationale, and description. Arch Gen Psychiatry 1992; 49(8): 624–9
Tatsch MF, Bottino CM, Azevedo D, et al. Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: prevalence and relationship with dementia severity. Am J Geriatr Psychiatry 2006; 14(5): 438–45
Landes AM, Sperry SD, Strauss ME. Prevalence of apathy, dysphoria, and depression in relation to dementia severity in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2005; 17(3): 342–9
Craig D, Mirakhur A, Hart DJ, et al. A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer’s disease. Am J Geriatr Psychiatry 2005; 13(6): 460–8
Thomas P, Clement JP, Hazif-Thomas C, et al. Family, Alzheimer’s disease and negative symptoms. Int J Geriatr Psychiatry 2001; 16(2): 192–202
Starkstein SE, Jorge R, Mizrahi R, et al. A prospective longitudinal study of apathy in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2006 Jan; 77(1): 8–11
Boyle PA, Malloy PF, Salloway S, et al. Executive dysfunction and apathy predict functional impairment in Alzheimer disease. Am J Geriatr Psychiatry 2003; 11(2): 214–21
Robert PH, Berr C, Volteau M, et al. Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer’s disease: a one-year follow-up study. Clin Neurol Neurosurg 2006; 108(8): 733–6
Ready RE, Ott BR, Grace J, et al. Apathy and executive dysfunction in mild cognitive impairment and Alzheimer disease. Am J Geriatr Psychiatry 2003; 11(2): 222–8
Robert PH, Berr C, Volteau M, et al. Neuropsychological performance in mild cognitive impairment with and without apathy. Dement Geriatr Cogn Disord 2006; 21(3): 192–7
Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157(1): 4–15
Cummings JL, Nadel A, Masterman D, et al. Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer’s disease. J Geriatr Psychiatry Neurol 2001; 14(2): 101–8
Cummings JL, Koumaras B, Chen M, et al. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: a 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 2005; 3(3): 137–48
Herrmann N, Rabheru K, Wang J, et al. Galantamine treatment of problematic behavior in Alzheimer disease: post-hoc analysis of pooled data from three large trials. Am J Geriatr Psychiatry 2005; 13(6): 527–34
Mega MS, Dinov ID, Porter V, et al. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study. Arch Neurol 2005; 62(5): 721–8
Kaufer D, Cummings JL, Christine D. Differential neuropsychiatric symptom responses to tacrine in Alzheimer’s disease: relationship to dementia severity. J Neuropsychiatry Clin Neurosci 1998; 10(1): 55–63
Galynker I, Ieronimo C, Miner C, et al. Methylphenidate treatment of negative symptoms in patients with dementia. J Neuropsychiatry Clin Neurosci 1997; 9(2): 231–9
Andreasen NC. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 1990; 24: 73–88
Deb S, Crownshaw T. The role of pharmacotherapy in the management of behaviour disorders in traumatic brain injury patients. Brain Inj 2004; 18(1): 1–31
Watanabe MD, Martin EM, DeLeon OA, et al. Successful methylphenidate treatment of apathy after subcortical infarcts. J Neuropsychiatry Clin Neurosci 1995; 7(4): 502–4
McAllister TW. Apathy. Semin Clin Neuropsychiatry 2000; 5(4): 275–82
Erkulwater S, Pillai R. Amantadine and the end-stage dementia of Alzheimer’s type. South Med J 1989; 82(5): 550–4
Chapman SB, Weiner MF, Rackley A, et al. Effects of cognitive-communication stimulation for Alzheimer’s disease patients treated with donepezil. J Speech Lang Hear Res 2004; 47(5): 1149–63
Holmes C, Knights A, Dean C, et al. Keep music live: music and the alleviation of apathy in dementia subjects. Int Psychogeriatr 2006; 18(4): 623–30
Verkaik R, van Weert JC, Francke AL. The effects of psychosocial methods on depressed, aggressive and apathetic behaviors of people with dementia: a systematic review. Int J Geriatr Psychiatry 2005; 20(4): 301–14
Politis AM, Vozzella S, Mayer LS, et al. A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. Int J Geriatr Psychiatry 2004; 19(11): 1087–94
Overshott R, Byrne J, Burns A. Nonpharmacological and pharmacological interventions for symptoms in Alzheimer’s disease. Expert Rev Neurother 2004; 4(5): 809–21
Boyle PA, Malloy PF. Treating apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord 2004; 17(1–2): 91–9
Acknowledgements
This study was partially supported with grants from the Raine Medical Research Foundation, and the National Health and Medical Research Council. The authors have no conflicts of interest that are directly relevant to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mizrahi, R., Starkstein, S.E. Epidemiology and Management of Apathy in Patients with Alzheimer’s Disease. Drugs Aging 24, 547–554 (2007). https://doi.org/10.2165/00002512-200724070-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200724070-00003